Table 2.
Description of GWAS consortiums used for each phenotype.
| Variable | First author (year) | Consortium | Sample size | Population | Adjustment |
|---|---|---|---|---|---|
| 25OHD | Revez25 | UKB | 417,580 | European | Sex, age, genotyping batch, assessment center, month of testing, supplement intake, and first 40 PCs |
| 25OHD | Jiang69 | SUNLIGHT | 79,366 | European | Sex, age, month of testing, BMI, and PCs |
| Forearm BMD | Zheng45 (2015) | GEFOS | 10,805 | European | Sex, age, and weight |
| Femoral neck BMD | 49,988 | European | |||
| Lumbar spine BMD | 44,731 | European | |||
| Total body BMD | Medina46 | GEFOS | 56,284 | European | Age, weight, height, and genomic PCs |
| Total body BMD (0–15) | 11,807 | 86%European | |||
| Total body BMD (15–30) | 4,180 | ||||
| Total body BMD (30–45) | 10,062 | ||||
| Total body BMD (45–60) | 18,805 | ||||
| Total body BMD (> 60) | 22,504 | ||||
| Heel BMD | Kim68 | UKB | 394,929 | European | Sex, age, and genotyping array |
25OHD 25-hydroxyvitamin D, BMD bone mineral density, UKB UK Biobank, SUNLIGHT Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits, GEFOS Genetic Factors for Osteoporosis, PC principal components, BMI body mass index. There is no sample overlap between 25OHD (Revez) and Forearm/Femoral neck/Lumbar spine/Total body BMD. There is no sample overlap between 25OHD (Jiang) and Heel BMD.